PT - JOURNAL ARTICLE AU - John R Giles AU - Derek AT Cummings AU - Bryan T Grenfell AU - Andrew J Tatem AU - Elisabeth zu Erbach-Schoenberg AU - CJE Metcalf AU - Amy Wesolowski TI - Trip duration drives shift in travel network structure with implications for the predictability of spatial disease spread AID - 10.1101/2020.10.27.20215566 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.27.20215566 4099 - http://medrxiv.org/content/early/2020/10/30/2020.10.27.20215566.short 4100 - http://medrxiv.org/content/early/2020/10/30/2020.10.27.20215566.full AB - Human travel is one of the primary drivers of infectious disease spread. Models of travel are often used that assume the amount of travel to a specific destination decays as cost of travel increases and higher travel volumes to more populated destinations. Trip duration, the length of time spent in a destination, can also impact travel patterns. We investigated the spatial distribution of travel conditioned on trip duration and find distinct differences between short and long duration trips. In short-trip duration travel networks, trips are skewed towards urban destinations, compared with long-trip duration networks where travel is more evenly spread among locations. Using gravity models imbedded in simulations of disease transmission, we show that pathogens with shorter generation times exhibit initial patterns of spatial propagation that are more predictable among urban locations, whereas longer generation time pathogens have more diffusive patterns of spatial spread reflecting more unpredictable disease dynamics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJRG and APW are supported by the National Library Of Medicine of the National Institutes of Health under Award Number DP2LM013102. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. APW is also funded by a Career Award at the Scientific Interface by the Burroughs Wellcome Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data used in this study was approved by the University of Southampton ERGO committee (ERGO ID 23647). No individuals were enrolled to participate because the data have been aggregated and de-identified. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to the data-sharing agreement with the mobile phone provider, the authors may not distribute the data used here. These data can be requested directly from MTC mobile (https://www.mtc.com.na/). Code to reproduce analyses is available upon request.